Last updated on August 2018

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations


Brief description of study

Phase II study to investigate the antitumor activity in terms of ORR of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.

Detailed Study Description

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors that carry HRAS mutations and for whom there is no curative therapy available. Subject with information available on tumor HRAS status previously generated are eligible. All subjects must consent to provide at least 10 tumor slides from a prior diagnostic biopsy for a retrospective testing of RAS gene status at a central facility.

Subjects will be enrolled into two nonrandomized cohorts:

  • Cohort 1: Malignant thyroid tumors with HRAS mutations.
  • Cohort 2: Squamous Head and Neck Cancer with HRAS mutations.

Clinical Study Identifier: NCT02383927

Contact Investigators or Research Sites near you

Start Over

Kamn Lacroix

University of California, Los Angeles
Los Angeles, CA United States
  Connect »

Kamn Lacroix

Dana-Farber Cancer Institute
Boston, MA United States
  Connect »

Kamn Lacroix

University of Michigan Comprehensive Cancer Center
Ann Arbor, MI United States
  Connect »

Kamn Lacroix

Mayo Clinic
Rochester, MN United States
  Connect »

Kamn Lacroix

Memorial Sloan-Kettering Cancer Center
New York, NY United States
  Connect »

Kamn Lacroix

University of Pennsylvania Hospital
Philadelphia, PA United States
  Connect »

Kamn Lacroix

Fox Chase Cancer Center
Philadelphia, PA United States
  Connect »

Kamn Lacroix

The University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Kamn Lacroix

University Hospital Antwerp
Antwerp, Belgium
  Connect »

Kamn Lacroix

Cliniques universitaires Saint-Luc
Brussels, Belgium
  Connect »

Kamn Lacroix

CHU
Yvoir, Belgium
  Connect »

Kamn Lacroix

Centre L on B rard
Lyon, France
  Connect »

Kamn Lacroix

Insitut Curie
Paris, France
  Connect »

Kamn Lacroix

Institute Gustave Roussy (IGR)
Paris, France
  Connect »

Kamn Lacroix

Instituto Nazionale Tumori
Milan, Italy
  Connect »

Kamn Lacroix

Asan Medical Center
Seoul, Korea, Republic of
  Connect »

Kamn Lacroix

Samsung Medical Center
Seoul, Korea, Republic of
  Connect »

Kamn Lacroix

University Medical Center
Groningen, Netherlands
  Connect »

Kamn Lacroix

Hospital Vall d' Hebron
Barcelona, Spain
  Connect »

Kamn Lacroix

Hospital del Mar
Barcelona, Spain
  Connect »

Kamn Lacroix

Hospital Universitario Doce de Octubre
Madrid, Spain
  Connect »

Kamn Lacroix

Start
Madrid, Spain
  Connect »

Kamn Lacroix

Beatson West of Scotland Cancer Centre
London, United Kingdom
  Connect »

Kamn Lacroix

Royal Marsden
London, United Kingdom
  Connect »

Kamn Lacroix

University College Hospital
London, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.